Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study.
Spitzer AI, Bockow BI, Brander VA, Yates JW, MacCarter DK, Gudger GK, Haller S, Lake SL, Magilavy DB. Spitzer AI, et al. Among authors: magilavy db. Phys Sportsmed. 2010 Jun;38(2):35-47. doi: 10.3810/psm.2010.06.1781. Phys Sportsmed. 2010. PMID: 20631462 Clinical Trial.
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB. Weinblatt ME, et al. Among authors: magilavy db. J Rheumatol. 2013 Apr;40(4):369-78. doi: 10.3899/jrheum.120923. Epub 2013 Feb 1. J Rheumatol. 2013. PMID: 23378467 Clinical Trial.
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. Weinblatt ME, et al. Among authors: magilavy db. N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22. N Engl J Med. 2010. PMID: 20879879 Free article. Clinical Trial.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB. Genovese MC, et al. Among authors: magilavy db. Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114. Arthritis Rheum. 2011. PMID: 21279990 Free article. Clinical Trial.
35 results